Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
- Conditions
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 141
- Registration Number
- NCT01929616
- Locations
- 🇧🇪
Hopital Erasme, Brussels, Belgium
🇧🇪Jules Bordet Institute, Brussels, Belgium
🇧🇪Centre hospitalier de Jolimont, Lobbes, Belgium
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT01913639
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 219
- Registration Number
- NCT01900743
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
🇦🇹LKH, Klagenfurt, Austria
🇫🇷Hôpital St Jacques, Besancon, France
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2020-10-06
- Target Recruit Count
- 118
- Registration Number
- NCT01896856
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2017-08-01
- Target Recruit Count
- 46
- Registration Number
- NCT01875380
- Locations
- 🇪🇸
Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain
Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
- Conditions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- National University Hospital, Singapore
- Registration Number
- NCT01189903
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Suzanne George, MD
- Target Recruit Count
- 34
- Registration Number
- NCT01068769
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.